Skip to content
OpenCapital
Get started

LivaNova LIVN Neuromodulation — Operating Income

Other segment segments

Cardiopulmonary
$30.07M+21.8%

Similar metrics at other companies

Hayward Holdings logo
HAYWNAM — Operating Income
$50.51M+16.2%
Marvell Technology, Inc. logo
MRVLOperating Income
$339.4M+25.4%
TEC
TECHDiagnostics And Spatial Biology — Operating Income
$10.32M+22.5%
GE HealthCare Technologies logo
GEHCOperating Income
$515M-18.1%
Edwards Lifesciences logo
EWOperating Income
$477.6M+21.0%
Ciena logo
CIENOperating Income
$237.87M+624%

Other financials

Income statement

See full
Revenue$362.3M+14.3%
Gross profit$243.7M+12.7%
Operating income$41.5M-14.7%
Net income$22.3M+107%
EPS (diluted)$0.40+107%

Balance sheet

See full
Cash & equivalents$539.7M-26.9%
Total debt$340.9M-49.7%
Total equity$1.2B+17.1%
Total assets$2.5B-1.7%

Cash flow

See full
Operating cash flow$15.2M-36.5%
CapEx$14.3M+32.4%
Free cash flow$926.0K-93.0%

Valuation

See full
Market cap$4.31B+62.8%
Enterprise value$4.11B+58.0%
P/S3×+0.9×

Profitability

See full
Gross margin67.5%-0.5pp
Operating margin13.4%+0.8pp
Net margin-16.1%-18.0pp
FCF margin11.2%-0.2pp

Returns & leverage

See full
Return on equity-17.6%-19.5pp
Debt / equity0.3×-0.4×
Current ratio1.3×-0.2×

Where this comes from

Reported directly by LivaNova in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: LivaNova’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about LivaNova's neuromodulation — operating income.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LivaNova's neuromodulation — operating income?
LivaNova (LIVN) reported neuromodulation — operating income of $44.15M in Q1 2026.
How has LivaNova's neuromodulation — operating income changed year-over-year?
LivaNova's neuromodulation — operating income decreased by 15.7% year-over-year, from $52.35M to $44.15M.
What is the long-term trend for LivaNova's neuromodulation — operating income?
Over 3 years (2021 to 2025), LivaNova's neuromodulation — operating income has grown at a 8.3% compound annual growth rate (CAGR), from $169.5M to $215.47M.
What does neuromodulation — operating income mean?
Calculated as the segment's net revenue minus cost of sales and operating expenses, excluding interest and taxes. It measures the core profitability and operational efficiency of the Neuromodulation business unit.